Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia

NCT ID: NCT05983172

Last Updated: 2023-08-14

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Total Enrollment: 1500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-08-31
• Study Completion Date: 2026-07-31

Brief Summary

The investigators will use machine learning to identify features on bone marrow smears and select features that are related to gene mutations, gene expression, or prognosis. The investigators will then use genome-wide transcriptomic profiling to investigate gene expression that is associated with patients' outcomes. The investigators will design a next-generation sequencing panel with unique molecular index and assess its feasibility and robustness in detecting measurable residual disease and optimize the panel/platform/bioinformatic pipeline. Finally, The investigators will use machine learning to integrate bone marrow smear features, gene mutations, gene expression, and measurable residual disease to construct a comprehensive risk assessment system that is based on multi-omics data. The investigators believe that such a platform will help physicians to design the most appropriate treatment strategies for individual patients, not only advancing the concept of precision medicine but also improving patients' prognoses.

Conditions

Acute Myeloid Leukemia

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Eligibility Criteria

Inclusion Criteria

1. Diagnosed with acute myeloid leukemia at the National Taiwan University Hospital

2. Ever enrolled in 201802021RINC、202109078RINB、201709072RINC

Exclusion Criteria

Nil

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Taiwan University Hospital

OTHER

Sponsor Role: lead

Responsible Party

National Taiwan University Clinical Trial Center

Assistant Professor and attending physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xavier Cheng-Hong Tsai, MD, MSc, PhD

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Locations

National Taiwan University Hospital

Taipei, , Taiwan

Countries

Taiwan

Other Identifiers

202306138RINB

Identifier Type: -

Identifier Source: org_study_id